BAJAJ BROKING

Notification close image
No new Notification messages
card image
Amanta Healthcare Ltd IPO
Apply for the Amanta Healthcare Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

15380

543904

MANKIND

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Mankind Pharma performance

Today’s low

Today’s high

₹ 2523.50 ₹ 2557.90
₹ 2545.90

52 week low

52 week high

₹ 2115.10 ₹ 3054.80
₹ 2545.90

Open Price

₹ 2538.90

Prev. Close

₹ 2520.90

Volume (Shares)

221886.00

Total traded value

₹ 5648.99

Upper Circuit

₹ 2772.90

Lower Circuit

₹ 2268.90

info

Mankind Pharma Share Price Update

As of the latest trading session, Mankind Pharma share price is currently at ₹ 2540, which is up by ₹ 19.10 from its previous closing. Today, the stock has fluctuated between ₹ 2523.50 and ₹ 2557.90. Over the past year, Mankind Pharma has achieved a return of 5.42 %. In the last month alone, the return has been -1.76 %. Read More...

Investment Returns

Over 1 Month -1.76% Over 3 Months 4.41% Over 6 Months 8.25% Over 1 Year 5.42%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Mankind Pharma fundamentals


  • Market cap (Cr)

    1,05,171.50

  • P/E Ratio (TTM)

    56.45

  • Beta

    0.66

  • Book Value / share

    354.71

  • Return on equity

    13.89%

  • EPS (TTM)

    43.85

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    412.76

info icon alternate text
  • Market cap (Cr)

    1,05,183.90

  • P/E Ratio (TTM)

    56.45

  • Beta

    0.63

  • Book Value / share

    354.71

  • Return on equity

    13.89%

  • EPS (TTM)

    43.85

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    412.76

info icon alternate text

Mankind Pharma Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 2541.36
Operating Expense 2111.92
Net Profit 412.76
Net Profit Margin (%) 16.24
Earnings Per Share (EPS) 10.00
EBITDA 737.29
Effective Tax Rate (%) 16.38
Particulars MAR 2025 (Values in Cr)
Revenue 2126.59
Operating Expense 1917.16
Net Profit 382.46
Net Profit Margin (%) 17.98
Earnings Per Share (EPS) 9.27
EBITDA 696.24
Effective Tax Rate (%) 10.79
Particulars DEC 2024 (Values in Cr)
Revenue 2414.41
Operating Expense 1959.69
Net Profit 412.02
Net Profit Margin (%) 17.06
Earnings Per Share (EPS) 10.35
EBITDA 816.47
Effective Tax Rate (%) 21.53
Particulars SEP 2024 (Values in Cr)
Revenue 2529.74
Operating Expense 1865.05
Net Profit 634.43
Net Profit Margin (%) 25.07
Earnings Per Share (EPS) 15.84
EBITDA 857.79
Effective Tax Rate (%) 21.80
Particulars JUN 2024 (Values in Cr)
Revenue 2412.62
Operating Expense 1934.54
Net Profit 505.66
Net Profit Margin (%) 20.95
Earnings Per Share (EPS) 12.82
EBITDA 672.08
Effective Tax Rate (%) 17.01
Particulars MAR 2025 (Values in Cr)
Revenue 9497.80
Operating Expense 7685.02
Net Profit 1945.48
Net Profit Margin (%) 20.48
Earnings Per Share (EPS) 48.16
EBITDA 3055.76
Effective Tax Rate (%) 18.28
Particulars MAR 2024 (Values in Cr)
Revenue 8629.25
Operating Expense 6714.55
Net Profit 1876.16
Net Profit Margin (%) 21.74
Earnings Per Share (EPS) 45.52
EBITDA 2536.79
Effective Tax Rate (%) 18.88
Particulars MAR 2023 (Values in Cr)
Revenue 8127.15
Operating Expense 6727.10
Net Profit 1248.26
Net Profit Margin (%) 15.35
Earnings Per Share (EPS) 31.16
EBITDA 1860.16
Effective Tax Rate (%) 20.12
Particulars MAR 2022 (Values in Cr)
Revenue 7486.22
Operating Expense 5818.59
Net Profit 1389.42
Net Profit Margin (%) 18.55
Earnings Per Share (EPS) 34.68
EBITDA 2041.88
Effective Tax Rate (%) 25.75
Particulars MAR 2021 (Values in Cr)
Revenue 5523.18
Operating Expense 4237.46
Net Profit 1084.37
Net Profit Margin (%) 19.63
Earnings Per Share (EPS) 27.07
EBITDA 1526.38
Effective Tax Rate (%) 24.70
Particulars MAR 2025 (Values in Cr)
Book Value / Share 347.37
ROE % 14.83
ROCE % 16.04
Total Debt to Total Equity 0.37
EBITDA Margin 26.60
Particulars MAR 2024 (Values in Cr)
Book Value / Share 233.73
ROE % 23.12
ROCE % 27.89
Total Debt to Total Equity 0.02
EBITDA Margin 27.40
Particulars MAR 2023 (Values in Cr)
Book Value / Share 185.61
ROE % 19.27
ROCE % 23.11
Total Debt to Total Equity 0.08
EBITDA Margin 23.35
Particulars MAR 2022 (Values in Cr)
Book Value / Share 153.65
ROE % 26.72
ROCE % 33.43
Total Debt to Total Equity 0.10
EBITDA Margin 28.29
Particulars MAR 2021 (Values in Cr)
Book Value / Share 117.88
ROE % 31.51
ROCE % 39.19
Total Debt to Total Equity 0.05
EBITDA Margin 29.48
Particulars MAR 2025 (Values in Cr)
Book Value / Share 354.83
ROE % 13.89
ROCE % 14.88
Total Debt to Total Equity 0.30
EBITDA Margin 28.95
Particulars MAR 2024 (Values in Cr)
Book Value / Share 242.21
ROE % 20.25
ROCE % 23.35
Total Debt to Total Equity 0.00
EBITDA Margin 27.90
Particulars MAR 2023 (Values in Cr)
Book Value / Share 194.31
ROE % 17.43
ROCE % 20.91
Total Debt to Total Equity 0.05
EBITDA Margin 22.89
Particulars MAR 2022 (Values in Cr)
Book Value / Share 163.27
ROE % 24.65
ROCE % 31.42
Total Debt to Total Equity 0.07
EBITDA Margin 27.28
Particulars MAR 2021 (Values in Cr)
Book Value / Share 118.18
ROE % 25.86
ROCE % 33.63
Total Debt to Total Equity 0.01
EBITDA Margin 27.64
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 554.50
Total Assets 27759.53
Total Liabilities 27759.53
Total Equity 14568.18
Share Outstanding 412578527
Price to Book Ratio 6.83
Return on Assets (%) 7.17
Return on Capital (%) 8.64
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 708.10
Total Assets 11963.25
Total Liabilities 11963.25
Total Equity 9575.79
Share Outstanding 400588440
Price to Book Ratio 9.48
Return on Assets (%) 15.98
Return on Capital (%) 19.58
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 453.19
Total Assets 9715.44
Total Liabilities 9715.44
Total Equity 7623.29
Share Outstanding 400588440
Price to Book Ratio 0.00
Return on Assets (%) 13.19
Return on Capital (%) 16.46
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 405.94
Total Assets 9147.73
Total Liabilities 9147.73
Total Equity 6316.31
Share Outstanding 400588440
Price to Book Ratio 0.00
Return on Assets (%) 15.67
Return on Capital (%) 19.95
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 700.74
Total Assets 6372.63
Total Liabilities 6372.63
Total Equity 4862.88
Share Outstanding 400588440
Price to Book Ratio 0.00
Return on Assets (%) 19.85
Return on Capital (%) 24.82
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 305.87
Total Assets 23828.32
Total Liabilities 23828.32
Total Equity 14640.27
Share Outstanding 412578527
Price to Book Ratio 6.83
Return on Assets (%) 8.16
Return on Capital (%) 8.89
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 483.88
Total Assets 11516.39
Total Liabilities 11516.39
Total Equity 9702.77
Share Outstanding 400588440
Price to Book Ratio 9.48
Return on Assets (%) 16.29
Return on Capital (%) 19.31
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 155.15
Total Assets 9371.12
Total Liabilities 9371.12
Total Equity 7783.91
Share Outstanding 400588440
Price to Book Ratio 0.00
Return on Assets (%) 13.32
Return on Capital (%) 16.04
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 138.84
Total Assets 8938.70
Total Liabilities 8938.70
Total Equity 6540.45
Share Outstanding 400588440
Price to Book Ratio 0.00
Return on Assets (%) 15.54
Return on Capital (%) 19.23
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 476.94
Total Assets 5880.33
Total Liabilities 5880.33
Total Equity 4734.27
Share Outstanding 400588440
Price to Book Ratio 0.00
Return on Assets (%) 18.44
Return on Capital (%) 22.45
Particulars MAR 2025 (Values in Cr)
Net Income 2524.78
Cash from Operations 2980.13
Cash from Investing -12682.95
Cash from Financing 10232.56
Net change in Cash -37.01
Free Cash Flow 3440.92
Particulars MAR 2024 (Values in Cr)
Net Income 2399.35
Cash from Operations 2593.97
Cash from Investing -2081.69
Cash from Financing 5.27
Net change in Cash 76.02
Free Cash Flow 2909.29
Particulars MAR 2023 (Values in Cr)
Net Income 1671.23
Cash from Operations 2136.39
Cash from Investing -1054.12
Cash from Financing -739.72
Net change in Cash 19.44
Free Cash Flow 2925.41
Particulars MAR 2022 (Values in Cr)
Net Income 1974.60
Cash from Operations 1419.28
Cash from Investing -1369.14
Cash from Financing 604.62
Net change in Cash 155.25
Free Cash Flow 1884.15
Particulars MAR 2021 (Values in Cr)
Net Income 1691.61
Cash from Operations 1591.31
Cash from Investing -1222.21
Cash from Financing -7.81
Net change in Cash -92.77
Free Cash Flow 1896.73
Particulars MAR 2025 (Values in Cr)
Net Income 2390.36
Cash from Operations 2793.64
Cash from Investing -12114.68
Cash from Financing 9845.34
Net change in Cash 52.82
Free Cash Flow 3092.06
Particulars MAR 2024 (Values in Cr)
Net Income 2325.72
Cash from Operations 2157.08
Cash from Investing -1665.19
Cash from Financing -4.73
Net change in Cash 66.16
Free Cash Flow 2374.95
Particulars MAR 2023 (Values in Cr)
Net Income 1562.83
Cash from Operations 2084.05
Cash from Investing -1040.61
Cash from Financing -710.41
Net change in Cash 47.96
Free Cash Flow 2632.41
Particulars MAR 2022 (Values in Cr)
Net Income 1871.43
Cash from Operations 1281.66
Cash from Investing -1360.26
Cash from Financing 578.62
Net change in Cash 39.80
Free Cash Flow 1583.01
Particulars MAR 2021 (Values in Cr)
Net Income 1440.20
Cash from Operations 1380.75
Cash from Investing -1127.15
Cash from Financing 88.86
Net change in Cash -54.91
Free Cash Flow 1570.94
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.16 12.72 1.70 238.79 30.00 / 69.50
BLISS GVS PHARMA LTD 158.10 15.64 1.58 1667.92 105.05 / 190.65
CIPLA LTD 1587.60 23.78 4.11 128239.04 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 322.55 9.08 2.61 949.30 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.16 16.93 4.92 238.79 30.00 / 69.50
AMRUTAJAN HEALTH LTD 720.55 38.21 6.37 2083.16 548.05 / 838.00
ASTRAZENECA PHARMA IND LT 8751.75 103.46 28.40 21879.38 6222.35 / 10653.05
BLISS GVS PHARMA LTD 158.10 23.63 1.57 1667.92 105.05 / 190.65

Mankind Pharma Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2548.20 1.08 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 2507.80
  • 26 Days 2519.70
  • 10 Days 2513.10
  • 50 Days 2507.30
  • 12 Days 2514.80
  • 100 Days 2487.50
  • 20 Days 2519.60
  • 200 Days 2460.80
2506.37 PIVOT

First Support

2486.53

First Resistance

2540.73

Second Support

2452.17

Second Resistance

2560.57

Third Support

2432.33

Third Resistance

2594.93

RSI

50.17

ADX

20.80

MACD

-4.91

Williams % R

-54.08

Commodity Channel Index (CCI)

-25.16

Date

2025-09-01

Week

239684.00

Same Day

207309.00

Month

334548.00

1 Year

0.67

3 Year

0.41

Over 1 Month

-1.76%

down

Over 1 Year

5.42%

down

Over 3 Months

4.41%

down

Over 3 Years

21.01%

down

Over 6 Months

8.25%

down

Over 5 Years

0.00%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

Mankind Pharma shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
2.74%
Promoter Holdings
72.67%
FII
13.07%
DII
11.5%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Ramesh Juneja Family Trust (held In The Name Of Ramesh Juneja, Managing Trustee) 8.3352652E7 (20.2%) Shareholding of Promoter and Promoter Group
Rajeev Juneja Family Trust (held In The Name Of Rajeev Juneja, Managing Trustee) 7.993052E7 (19.37%) Shareholding of Promoter and Promoter Group
Prem Sheetal Family Trust (held In The Name Of Arora Family Private Limited, Trustee) 6.1755635E7 (14.96%) Shareholding of Promoter and Promoter Group
Sheetal Arora 1.9277647E7 (4.67%) Shareholding of Promoter and Promoter Group
Puja Juneja 1.1533906E7 (2.79%) Shareholding of Promoter and Promoter Group
Poonam Juneja 1.0557626E7 (2.56%) Shareholding of Promoter and Promoter Group
Arjun Juneja 8154463.0 (1.98%) Shareholding of Promoter and Promoter Group
Ramesh Juneja 6855990.0 (1.66%) Shareholding of Promoter and Promoter Group
Government Pension Fund Global 6707671.0 (1.63%) Public Shareholding
Nps Trust A/c - Sbi Pension Fund - Ups - Cg Scheme 6561870.0 (1.59%) Public Shareholding
Rajeev Juneja 6500021.0 (1.57%) Shareholding of Promoter and Promoter Group
Sbi Healthcare Opportunities Fund 5999673.0 (1.45%) Public Shareholding
Axis Mutual Fund Trustee Limited A/c Axis Mutual Fund 4842761.0 (1.17%) Public Shareholding
Sbi Life Insurance Co. Ltd. 4412511.0 (1.07%) Public Shareholding
Chanakya Juneja 3896788.0 (0.94%) Shareholding of Promoter and Promoter Group
Eklavya Juneja 3896788.0 (0.94%) Shareholding of Promoter and Promoter Group
Mishka Arora 2955692.0 (0.72%) Shareholding of Promoter and Promoter Group
Ria Chopra Juneja 1292884.0 (0.31%) Shareholding of Promoter and Promoter Group
Greesh Kumar Juneja 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rajeev Juneja And Sons Huf (rajeev Juneja - Karta) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
R C Juneja And Sons Huf (ramesh Juneja- Karta) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Kusum Lata Dua 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mohit Vij 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rekha Vij 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Yogi Raj Vij 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Viralika Arora 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Esha Arora Tewari 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Nidhi Arora 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Prabha Arora 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Prem Kumar Arora 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Gautam Madan 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Sanjay Madan 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Asha Madan 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ashok Kumar 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Geeta Agarwal 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rajeev Mohan Agarwal 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pushpa Rani Aggarwal 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ayushi Juneja Sikri 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Twin Roots Ventures Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Wellspur Foundation 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Acche Karam Hospitality Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
A To Z Packers 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Anm Holdings Pte Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Casablanca Pharma Pte Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Salute Bestochem Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Petal Pharma Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Biovein Innovative Solutions Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Bigbrother Nutra Care Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Besto Herbs Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Quality Bestochem Formulations Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
G.a. Davai India Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Bestochem Formulations (india) Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Virmish Enterprises Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Teen Murti Products Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Star Infra Developers Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Saburi Sai Ram Buildtech Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Saburi Projects Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Saburi Enterprises Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Saburi Consultants Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rpj Trustee Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rotokind Technologies 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rcj Advisors Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rashmi Exports Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rashi Apparels Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Printman 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pp & A Combines Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Pathkind Diagnostics Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Paonta Process Equipments 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Om Sai Pharma Pack 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Nextwave India Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mankind Drugs Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mankind Biotech Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Appian Multiventures Private Limited (formerly Known As Mankind Biosys Private Limited) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Luxor Metaltec (india) Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
J & A Partners 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Intercity Corporate Towers Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Gyan Infrastructure Company Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Casablanca Securities Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Casablanca Pharma Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Casablanca Lifesciences Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Beckon Realestate Developers Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ayushi And Poonam Estates Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Arora Family Pvt Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Appian Projects Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Appian Buildwell Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Appian Buildrise Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Appian Buildheights Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Appian Associates Infrastructure Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Anm Properties Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Alankrit Handicrafts Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ajs Properties 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ace Overseas Ventures 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

Mankind Pharma corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
08 Aug 2025 1.0 Interim 08 Aug 2025 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
08 Aug 2025 1.0 Interim 08 Aug 2025 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Mankind Pharma Share Price

Mankind Pharma Limited was incorporated on July 3, 1991, as a Private Limited Company with the name 'Mankind Pharma Private Limited', by the Registrar of Companies, Delhi and Haryana, at New Delhi. Pursuant to conversion of Company to a Public Limited dated July 14, 2005, name of the Company was changed to 'Mankind Pharma Limited' and the RoC issued a fresh Certificate of Incorporation on April 13, 2006.

The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across, as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals / nutrients and respiratory.

In 2004, the Company entered the chronic pharmaceutical segment with the launch of Amlokind' tablets and Glimestar' tablets amongst others. It set up their first manufacturing facility at Paonta Sahib, in Himachal Pradesh during year 2005. It entered the ophthalmic pharmaceutical segment with the launching of Lubistar Eye Drops' and Tobastar Eye Drops'.

In 2007, the Company diversified into the consumer healthcare segment with the launch of Manforce' brand and have since established several differentiated brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral
supplements and anti-acne preparations categories. It entered into the business of animal healthcare segment and launched Bandykind' and Ceftiforce'. It established their Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh in year 2009.

It launched the brand, Preganews' into the consumer healthcare segment in year, 2010. In 2012, it set up their first R&D centre at IMT Manesar, in Haryana. Thereafter, in year 2014, the Company acquired Shree Jee Laboratory Private Limited along with its API manufacturing site at Behror, Rajasthan. It set up the Unit II manufacturing facility at Paonta Sahib, Himachal Pradesh.

In 2015, subsidiaries like Lifestar Pharma LLC in the US and Mankind Pharma Pte. Limited in Singapore were formed into with the Company.

In 2017, a new manufacturing facility got established in Sikkim.

In 2019, the Company entered into female infertility business segment and launched Dydroboon' tablets.

In 2020, a subsidiary, Lifestar Pharmaceuticals Private Limited was formed in Nepal. The Company introduced a specialty therapeutic division for cardiovascular diseases (CVD) drugs segment and launched Cilaheart' tablets and Statpure' tablets in the market. It launched Zukanorm' tablets for diabetes pharmaceuticals segment.

Another new subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE got incorporated during the year 2021. It launched Mlife' tablets in the specialty division for therapeutic respiratory pharmaceuticals. It entered into specialty therapeutic neuro/central nervous system pharmaceuticals segment business with the launch of Trugaba-NT' tablets and Prebris-MNT' tablets.

In 2022, the Company acquired formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited. Further, it entered into the transplant segment with the launch of Pangraf Capsules' and Mycept' tablets. It entered into the business of oncology segment with the launch of injection Pacliall'. It acquired Daffy' and Combihale' brands from Dr. Reddy's Laboratories.

The Company operate 23 manufacturing facilities across India and had 2,181 manufacturing personnel as of March 31, 2022. Their formulations manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products, as of March 31, 2022.

In April 2023, Company made an Initial Public Offer of 40,058,844 Equity Shares by raising funds aggregating to Rs 4326.35 Crore through Offer for Sale.

During the FY 2022-23, the Company acquired 90% shareholding of Upakarma Ayurveda Private Limited, pursuant to which Upakarma Ayurveda became a step down subsidiary of the Company. Further, it also acquired 100% shareholding of Mankind Agritech Private Limited, making Mankind Agritech a wholly owned subsidiary of the Company. The Company also acquired minority stake of 6.30% in Actimed Therapeutics Limited.

The erstwhile wholly owned subsidiaries, Lifestar Pharma Private Limited and Magnet Labs Private Limited got amalgamated with the Company and the Scheme of Amalgamation became effective from March 30, 2023.

During the FY 2023-24, Mankind Medicare Private Limited was incorporated as the wholly owned subsidiary of the Company. The Company sold the Over the Counter (OTC) business of the Company to Mankind Consumer Products Private Limited, Wholly Owned Subsidiary Company as a going concern via slump sale on April 2, 2024. On October 23, 2024, Company acquired a 100% stake in Bharat Serums and Vaccines Limited (BSV), making it a wholly owned subsidiary of the Company. Urology Specialty Division launched in FY 2025.

Parent organization Indian Private
NSE symbol MANKIND
Founded 1991
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Mankind Pharma Ltd?

Answer Field

Mankind Pharma Ltd share price is for NSE ₹ 2,540.00 & for BSE ₹ 2,545.00 as on Sep 02 2025 03:29 PM.

What is the Market Cap of Mankind Pharma Ltd Share?

Answer Field

The market cap of Mankind Pharma Ltd for NSE ₹ 1,04,794.90 & for BSE ₹ 1,05,001.20 as on Sep 02 2025 03:29 PM.

What is the 52 Week High and Low of Mankind Pharma Ltd?

Answer Field

The 52 Week High and Low of Mankind Pharma Ltd for NSE is ₹ 3,054.80 and ₹ 2,115.10 and for BSE is ₹ 3,050.00 and ₹ 2,115.50.

What is 1 year return for Mankind Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 5.42%.

What is the P/E Ratio of Mankind Pharma Ltd Share?

Answer Field

As on Sep 02 2025 03:29 PM the price-to-earnings (PE) ratio for Mankind Pharma Ltd share is 56.45.

What is the PB ratio of Mankind Pharma Ltd Share?

Answer Field

As on Sep 02 2025 03:29 PM, the price-to-book (PB) ratio for Mankind Pharma Ltd share is 354.71.

How to Buy Mankind Pharma Ltd Share?

Answer Field

You can trade in Mankind Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Mankind Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Mankind Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Mankind Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91